Eli Lilly investors have suffered an unexpected bear market as recent headwinds buffeted the stock. Notwithstanding near-term execution challenges, Lilly's weight loss drugs are gaining more share. Potential policy changes under the Biden administration could benefit Lilly, but they are unlikely to be resolved before Trump takes office.

Hertz Energy (CSE:HZ, OTCQB:HZLIF) announced that it will consolidate its common shares on a four-for-one basis, The move, effective December 12, 2024, will reduce the total number of outstanding shares to approximately 16.5 million, down from the current amount, with adjustments made for fractional shares. Following the consolidation, Hertz Energy (CSE:HZ, OTCQB:HZLIF)'s name and trading symbols will remain unchanged.

Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts.

Rambus, despite past challenges, is now an appealing buy at 28x forward free cash flow, with over 5% of its market cap in cash. The company specializes in memory interface chips and chipsets, with strong growth driven by DDR5 adoption and data center demand. While revenue growth rates are erratic, Rambus' robust balance sheet and leading memory technologies offer a solid investment opportunity.

HOLX will unveil breakthrough innovations at this year's RSNA, focusing on imaging solutions and AI.

REITs are presenting a historic opportunity. Their valuations are the lowest since the great financial crisis. We present 3 REITs offering significant upside potential.

Alstom's recovery and growth potential make it a strong long-term investment, with significant improvements in backlog mix, capital raises, and KPIs. The company's European-centric portfolio, especially in rolling stock and signaling, positions it well for future infrastructure growth and electrification trends. Despite past challenges and a significant share price drop, Alstom's deleveraging and strategic focus on high-margin segments support a positive outlook.

In our commercial-legal cultures, we hate monopolies but tolerate duopolies. An application watching-observability Dynatrace and Datadog may be evolving toward becoming an informal duopoly. On the surface, the two companies seem very much alike.

Leading vaccine makers like Eli Lilly and Co. NYSE: LLY, Pfizer Inc. NYSE: PFE, and AstraZeneca plc NASDAQ: AZN may have faded from the spotlight since the peak of the COVID-19 pandemic, but now there is reason to expect renewed interest. As investors look ahead to the second Trump administration, the incoming president's nomination of outspoken vaccine critic Robert F.

The Estee Lauder Companies faces challenges due to weak consumer sentiment in China and Asia travel retail, leading to disappointing performance.